Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy

Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy
Allogene pushes M and A in cell therapy

Allogene Therapeutics announced that Daniel Hunt, Vice President of Corporate and Business Development, is participating at FiercePharmaEngage to engage in discussions around the evolution of merger and acquisition strategies for allogeneic CAR T therapies.

The company is focusing on leveraging M and A to accelerate innovation, expand access to new cell therapy treatments, and build on its expertise in the sector. The event brings together industry stakeholders to examine strategic initiatives aimed at expanding the therapeutic landscape and improving market access across the cell therapy segment.

Allogene has previously driven innovation in CAR T therapy, aiming to broaden patient access and pursue new cell treatment advances, according to an earlier update (Allogene Therapeutics drives innovation in CAR T therapy). The company has also released interim ALPHA3 trial data showing early potential for allogeneic CAR T in LBCL treatment (Allogene Therapeutics advances allogeneic CAR T interim results). The latest participation at FiercePharmaEngage follows these developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.